6831-54-5

Basic information

• Product Name: (3,4-Dimethyl-phenyl)-acetylchlorid
• Synonyms: (3,4-Dimethyl-phenyl)-acetylchlorid
• CAS NO: 6831-54-5
• Molecular Weight: 182.65
• Mol File: 6831-54-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (3,4-Dimethyl-phenyl)-acetylchlorid(CAS DataBase Reference)
• NIST Chemistry Reference: (3,4-Dimethyl-phenyl)-acetylchlorid(6831-54-5)
• EPA Substance Registry System: (3,4-Dimethyl-phenyl)-acetylchlorid(6831-54-5)

Safety Data

• Hazardous Substances Data: 6831-54-5(Hazardous Substances Data)

Upstream product

• 17283-16-8 3,4-dimethylphenylacetic acid 

Downstream Products

• 127021-95-8 4-[1-(3,4-Dimethyl-benzylcarbamoyl)-3,3-diethyl-4-oxo-azetidin-2-yloxy]-benzoic acid 
• 916646-43-0 4-Isocyanatomethyl-1,2-dimethyl-benzene 
• 592529-15-2 2-(3,4-dimethyl-phenyl)-1-{2-[2-(4-methylsulfanyl-phenyl)-2-oxo-ethyl]-pyrrolidin-1-yl}-ethanone 
• 85175-47-9 N-(2,2-dimethoxyethyl)-3,4-dimethyl-phenylacetamide 

Relevant articles and documents

Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a new class of compounds exerting antiischemic properties

Structural modification of the calcium-antagonist verapamil (1) by replacement of the lipophilic α-isopropylacetonitrile moiety by various heterocyclic ring systems has led to a new class of cardiovascular compounds which are characterized by a specific bradycardic activity. These agents reduce heart rate without binding to classical calcium channels or β-adrenoceptors, interacting instead specifically with structures at the sino atrial node. Therefore they have also been termed sinus node inhibition. The prototype falipamil (2) has been submitted to furthr optimization mainly hy manipulation of the phthalimidine moiety. This has resultd in a secod generation of specific bradycardic agents with increased potency and selectively and prolonged duration of action represented by the benzazepinone-derivative UL-FS 49 (4). Structure-activity relationships within this novel class of compounds have revealed a marked dependence of activity on the substitution pattern of the aromatic rings, the nature of the central nitrogen atom, and the length of the connecting alkyl chains. The crucial role of the benzazepione ring for bradycardic activity can be best explained by its special impact on the overall molecular conformation.

Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers

A novel class of tetrazole-derived Kv1.5 blockers is disclosed. In in vitro studies, several compounds had IC50s ranging from 180 to 550 nM. In vivo studies indicated that compounds 2f and 2j increased right atrial ERP about 40% without affecting ventricular ERP.

Orally Active β-Lactam Inhibitors of Leukocyte Elastase-1. Activity of 3,3-Diethyl-2-azetidinones

A thorough analysis of the mechanism of inhibition of human leukocyte elastase (HLE) by a monocyclic β-lactam and the mechanism of β-lactam hydrolysis led to the preparation of potent and highly stable inhibitors of HLE.This work led to the identification of 4--3,3-diethyl-1-carbonyl>-2-azetidinone (2) as the first orally active inhibitor of human leukocyte elastase (HLE).Analogs of 2 with different substituents on the urea N were synthesized and evaluated for their activity in vitro against HLE as well as in vivo in a hamster lung hemorrhage model.Compounds with a methyl or a methoxy group in the para position of the benzene ring were very potent in both assays.The results are discussed on the basis of the proposed model for the binding of this class of inhibitors to HLE and a possible mechanism of inhibition is presented.